SCHEMBL4859209

SCHEMBL4859209

COc1cc(Cl)cc(OCc2cncs2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
PARP15 Q460N3 1/20 0.45
PARP10 Q53GL7 1/20 0.45
SLC6A3 Q01959 5/20 0.40
LMNA P02545 3/20 0.39
RAB9A P51151 2/20 0.39
NPC1 O15118 1/20 0.39
HTT P42858 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
MAPT P10636 1/20 0.37
SLC6A4 P31645 1/20 0.37
ACACB O00763 1/20 0.37
NMT1 P30419 1/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
TDP1 Q9NUW8 1/20 0.35
GRM5 P41594 1/20 0.35
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4858769 0.71 PLK1 (0.48) MEN1KMT2AHTTCYP1A2SLC6A4
SCHEMBL28530451 0.70 ENPP2 (0.43) MEN1KMT2ALMNARAB9ANPC1
SCHEMBL4851777 0.70 HTR1A (0.51) LMNAHTTSLC6A4GRM5
SCHEMBL272571 0.69
SCHEMBL12015518 0.69 PARP15 (0.49) KMT2APARP15PARP10RAB9ANPC1
SCHEMBL21263 0.69 ALDH1A1 (0.69) CYP1A2CYP2C9CYP2C19CYP1A1CYP1B1
SCHEMBL5726200 0.67 MAPT (0.47) MEN1KMT2AMAPTL3MBTL1TDP1
SCHEMBL4852115 0.67 MAOB (0.67) MEN1KMT2ASLC6A3LMNACYP1A2
SCHEMBL15474277 0.67 PARP15 (0.47) PARP15PARP10SLC6A3RAB9ANPC1
SCHEMBL15607658 0.67 PARP15 (0.54) PARP15PARP10LMNARAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456169-B2 Heterocyclic kinase inhibitors ABBOTT LABORATORIES INC. (US) 2008-11-25 US disclosed
US-20070254867-A1 Heterocyclic Kinase Inhibitors ABBVIE INC. 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254867-A1 Heterocyclic Kinase Inhibitors MAP3K20, MAP3K19, MAP4K2 MEN1 2238/4885KMT2A 1376/4885PARP15 1031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.